Abstract:Background: Cardiovascular diseases (CVD) are the leading cause of death in the United States. Statins, a class of hydroxy-methylglutaryl-coenzyme A reductase (HMGCR) inhibitors, have been proven to be effectively prevent and treat CVD by improving vascular functions independent of their cholesterol-lowering effect. However, the molecular mechanisms by which statins improve cardiovascular functions remain elusive. In this study, we used human induced pluripotent stem cells-derived endothelial cells (hiPSC-ECs) to explore the protective role of statins in the vascular system. Methods and Results: hiPSCs were generated from 3 healthy individuals and differentiated into endothelial cells using two different iPSC clones and two batches (4 biological replicates for each individual). hiPSC-ECs of each individual were treated with simvastatin or a vehicle control. The RNA-sequencing analysis was performed on 12 control and 12 statin-treated hiPSC-ECs. A total number of 2,580 differentially expressed genes (DEGs) were found in simvastatin-treated hiPSC-ECs. Gene enrichment analysis revealed that statin-upregulated DEGs were highly enriched in angiogenesis and anti-inflammation pathways. Interestingly, statin-downregulated DEGs were significantly enriched in epigenetic regulation and nucleosome assembly pathways, suggesting an epigenetic regulatory role of stains in vascular gene expression. To test this hypothesis, we further performed the Assay for Transposase-Accessible Chromatin using sequencing (ATAC-seq) analysis on vehicle or simvastatin treated hiPSC-ECs. Transcription factor (TF) binding motif analyses of ATAC-seq peaks using HOMER revealed that YAP/TEAD binding was the most significantly downregulated TF after statin treatment. Furthermore, we observed that statin can improve endothelial functions (e.g., angiogenesis and nitric oxide production) after the YAP activity was inhibited. The ChIP-seq analysis showed that statin downregulated the expression levels of genes associated with the endothelial-to-mesenchymal transition (EndoMT) by attenuating the binding capacity of YAP. As such, simvastatin effectively rescued diabetic vascular dysfunction mainly through inhibiting EndoMT. Conclusion: We found that statins can improve endothelial functions through attenuating the chromatin accessibility of EndoMT-related genes, a process tightly regulated by the activity of YAP. These findings will provide novel insights into the protective mechanisms of statins in the cardiovascular system beyond their cholesterol-lowering effects.

Simvastatin reduces lipoprotein-associated phospholipase A 2 in lipopolysaccharide-stimulated human monocyte-derived macrophages through inhibition of the mevalonate-geranylgeranyl pyrophosphate-RhoA-p38 mitogen-activated protein kinase pathway

[Simvastatin Suppress Lipopolysaccharides Induced Upregulation of Lipoprotein Associated Phospholipase A(2) Expression in Macrophages Via Inactivation of P38mapk Pathway].

Simvastatin Inhibits Inflammatory Response in Lipopolysaccharide (Lps)-Stimulated RAW264.7 Macrophages Through the Microrna-22/Cyr61 Axis.

Simvastatin Reduces Expression and Activity of Lipoprotein-Associated Phospholipase A(2) in the Aorta of Hypercholesterolaemic Atherosclerotic Rabbits.

Effect of simvastatin on cholesterol efflux and expression of ABCA1 and CD36 in THP-1 macrophages

Simvastatin Increases Prolyl-4-Hydroxylase Α1 Expression in Atherosclerotic Plaque and Ox-Ldl-stimulated Human Aortic Smooth Muscle Cells Via P38 MAPK and ERK1/2 Signaling.

Cyclic nucleotides and mitogen-activated protein kinases: regulation of simvastatin in platelet activation

Simvastatin inhibits homocysteine-induced CRP generation via interfering with the ROS-p38/ERK1/2 signal pathway in rat vascular smooth muscle cells

Opposite effects of simvastatin on the bactericidal and inflammatory response of macrophages to opsonized S. aureus

Statins attenuate antiviral IFN‐β and ISG expression via inhibition of IRF3 and JAK/STAT signaling in poly(I:C)‐treated hyperlipidemic mice and macrophages

Simvastatin Attenuates Lipopolysaccharide-Induced Airway Mucus Hypersecretion in Rats

Simvastatin Suppresses the Proangiogenic Microenvironment of Human Hepatic Stellate Cells Via the Kruppel-like Factor 2 Pathway.

Inhibition of EphA2 protects against atherosclerosis by synergizing with statins to mitigate macrophage inflammation

E0070 Atorvastatin Suppresses Inflammatory Response Induced by Oxldl Through Inhibition of ERK Phosphorylation, IκB? Degradation and COX-2 Expression in Murine Macrophages

Simvastatin Suppressed HMGB1-RAGE Axis and Atherosclerosis Via Mevalonate Pathway

Abstract 325: The Regulation of Endothelial Function Through Hmgcr/mevalonate Pathway Mediated Yap Activity

Statins Induce the Accumulation of Regulatory T Cells in Atherosclerotic Plaque

The Rapid Lipopolysaccharide-Induced Release of Matrix Metalloproteinases 9 is Suppressed by Simvastatin

Statin-mediated reduction in mitochondrial cholesterol primes an anti-inflammatory response in macrophages by upregulating Jmjd3

Simvastatin suppresses vascular inflammation and atherosclerosis in ApoE−/− mice by downregulating the HMGB1-RAGE axis